Evidence map›Paper›PMID 35104298›Full record

ArticlePloS one2022

Is repeat serum urate testing superior to a single test to predict incident gout over time?

Sarah Stewart, Amanda Phipps-Green, Greg D Gamble, Lisa K Stamp, William J Taylor, Tuhina Neogi, Tony R Merriman, Nicola Dalbeth

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Sarah StewartDepartment of Medicine, University of Auckland, Grafton, Auckland, New Zealand.ORCID 0000-0002-9318-5627
Amanda Phipps-GreenDepartment of Medicine, University of Otago Dunedin, Dunedin Central, Dunedin, New Zealand.
Greg D GambleDepartment of Medicine, University of Auckland, Grafton, Auckland, New Zealand.ORCID 0000-0003-0412-3203
Lisa K StampDepartment of Medicine, University of Otago Christchurch, Christchurch Central City, Christchurch, New Zealand.
William J TaylorDepartment of Medicine, University of Otago Wellington, Newtown, Wellington, New Zealand.
Tuhina NeogiSchool of Medicine, Boston University Medical School, Boston, Massachusetts, United States of America.
Tony R MerrimanDepartment of Medicine, University of Otago Dunedin, Dunedin Central, Dunedin, New Zealand.
Nicola DalbethDepartment of Medicine, University of Auckland, Grafton, Auckland, New Zealand.
University of Otago · NZUniversity of Auckland · NZBoston University · US

Funding

Research and Evaluation Support Core Unit (RESCU Core)P30AR072571 · NIAMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Michael Paul Lavalley · 2019 to 2026
$6.9M
NIAMS NIH HHS P30 AR072571
6 · The paper itself

Abstract

Elevated serum urate is the most important causal risk factor for developing gout. However, in longitudinal cohort studies, a small proportion of people with normal urate levels develop gout and the majority of those with high urate levels do not. These observations may be due to subsequent variations in serum urate over time. Our analysis examined whether single or repeat testing of serum urate more accurately predicts incident gout over time. Individual participant data from three publicly-available cohorts were included. Data from paired serum urate measures 3-5 years apart, followed by an assessment of gout incidence 5-6 years from the second urate measure were used to calculate the predictive ability of four measures of serum urate on incident gout: the first measure, the second measure, the average of the two measures, and the highest of the two measures. Participants with prevalent gout prior to the second measure were excluded. Receiver operator characteristic (ROC) curves and area under the curve (AUC) statistics were computed to compare the four measures. A total of 16,017 participants were included across the three cohorts, with a mean follow-up from the first serum urate test of 9.3 years (range 8.9-10.1 years). Overall, there was a small increase in the mean serum urate between the first and second measures (322 μmol/L (5.42 mg/dL) vs. 340 μmol/L (5.71 mg/dL), P<0.001) which were a mean of 3.5 years apart, but the first and second measures were highly correlated (r = 0.81, P<0.001). No differences were observed in the predictive ability of incident gout between the four measures of serum urate measurement with ROC curve AUC statistics ranging between 0.81 (95% confidence intervals: 0.78-0.84) and 0.84 (95% confidence intervals: 0.81-0.87). These data show that repeat serum urate testing is not superior to a single measure of serum urate for prediction of incident gout over approximately one decade.

Indexed as

AdultArea Under CurveFemaleGoutHumansIncidenceLongitudinal StudiesMaleMiddle AgedROC CurveSensitivity and SpecificityUric AcidUric Acid

Identifiers

PMID35104298
PMCPMC8806054
OpenAlexW4210530666

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.